Using RNA expression data from both microarray and mRNA sequencing, we confirmed that overexpression of CPT1A is a marker of poor prognosis correlating with decreased overall survival in all breast cancer patients (p = 0.0035) and specifically in HER2+ breast tumors (p = 0.00071) (Fig. 7a). Here, ERBB2 is linked to breast carcinoma.